Trial Profile

An Open-Label Cross-Over Study to Compare Bioavailability, Dose Proportionality, and Palatability of Single Doses of BMS-986165 Minitablet Pediatric Formulation in Fasted and Fed Conditions Relative to Single Doses of BMS-986165 Clinical Formulations In Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucravacitinib (Primary)
Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

09 Nov 2021 Status changed from not yet recruiting to completed.
07 Aug 2020 Planned End Date changed from 6 Jun 2020 to 22 Nov 2020.
07 Aug 2020 Planned primary completion date changed from 6 Jun 2020 to 22 Nov 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com